Regeneron Pharma (REGN) PT Lowered to $180 at Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $930.67 -4.39%
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Wells Fargo analyst Brandon Couillard lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $180.00 (from $190.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Procore Technologies, Inc (PCOR) PT Raised to $90 at BTIG
- ArcBest Corp (ARCB) PT Lowered to $146 at TD Cowen
- GlobalFoundries Inc. (GFS) PT Lowered to $50 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
